Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany

Abstract

There was no significant efficacy and cost difference between therapy alternatives in base cases. However, in the majority of scenarios in the sensitivity analyses, EMT was a more cost-effective option in acute HCV therapy.

Il28B Cc-Genotype Association with Hla-Dqb1*0301 Allele Increases the Prediction of Spontaneous HCV RNA Clearance in Thalassaemic HCV-Infected Patients

“…Unfortunately, the onset of acute HCV infection is asymptomatic in 2/3 of cases and, so far, there are no means to identify early patients who will develop chronic infection. Conversely, antiviral treatment is highly effective when administered during the acute phase [2,3]. Therefore, making the decisions to immediately start therapy or wait for spontaneous HCV clearance has become critical and the identification of baseline predictors able to assist physicians in treatment decision represents a matter of investigation [4][5][6].…”

Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System

“…The remainder progress to chronic infection. 4,5 As many as 40% progress asymptomatically to cirrhosis and hepatocellular carcinoma (HCC), with an increased risk of premature death. [6][7][8] Fortunately, treatment for chronic hepatitis C (CHC) changed significantly with the advent of interferon-free direct-acting antiviral agents (DAAs) in 2014.…”